+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

Global Rheumatoid Arthritis Market 2019-2025

  • PDF Icon

    Report

  • May 2020
  • Region: Global
  • Orion Market Research Private Limited
  • ID: 5129628
UP TO OFF until Dec 31st 2022
Global Rheumatoid Arthritis Market Size, Share & Trends Analysis Report by Treatment (Medications and Surgery) and Forecast 2019-2025.

The global rheumatoid arthritis market is projected to witness considerable growth during the forecast period. The major factors contributing to the growth of the market include the increasing prevalence of diabetes and adoption of sedentary lifestyle. With the increasing prevalence of diabetes, measures for diagnosis and treatment are growing at a significant rate, thus, supporting the global rheumatoid arthritis market. The rheumatoid arthritis market is classified on the basis of treatment, which includes medication and surgery. The market for rheumatoid arthritis medications is further segmented into nonsteroidal anti-inflammatory drugs (NSAIDs), disease-modifying anti-rheumatic drugs (DMARDs), biologics, and steroidal medications. Among these medications, DMARDs are one of the major medications prescribed by the rheumatologists for the treatment of rheumatoid arthritis.

Geographically, the global rheumatoid arthritis market is segmented into North America, Europe, Asia-Pacific, and Rest of the World. North America is expected to contribute a significant share in the global market. The growing prevalence of diabetes and fast-moving lifestyle in the US and the presence of major market players, such as Pfizer Inc. and AbbVie Inc., are the factors that are driving the market in this region. Asia-Pacific is expected to project a considerable growth rate in the market during the forecast period. The increasing expenditure of healthcare infrastructure in the emerging economies of the region, such as China and India, is increasing adoption advanced technologies. In addition, the increasing geriatric population in the region have augmented prevalence rate of diabetes, which in turn, is significantly offering growth factor to the rheumatoid arthritis market in the region.

The global rheumatoid arthritis market is influenced by product development and advancements conducted by the market players. The key players of the rheumatoid arthritis market include Amgen Inc., Pfizer Inc., AbbVie Inc., Sanofi SA, Bristol-Myers Squibb Co. Apart from these market players, some other companies that are significantly contributing in the global rheumatoid arthritis market growth includes Eli Lilly and Co., F. Hoffmann-La Roche Ltd., Regeneron Pharmaceuticals Inc., GlaxoSmithKline PLC, Teva Pharmaceutical Industries Ltd., UCB S.A., and Biogen Inc. These players are playing a significant role in the growth of the rheumatoid arthritis market by providing various products and adopting several strategies such as merger and acquisition, partnerships and collaboration, technological development, and others.

Research Methodology

The market study of the global rheumatoid arthritis market is incorporated by extensive primary and secondary research conducted by the research team. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. The team collects facts and data related to the market from different geography to provide a better regional outlook.

In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables the analyst to derive the closest possible figures without any major deviations in the actual number. The analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings the authenticity of the reports.

Secondary sources include:
  • Financial reports of companies involved in the market
  • Whitepapers, research-papers, and news blogs
  • Company websites and their product catalog

The report provides an in-depth analysis of the market size and growth opportunities. The report will serve as a source for 360-degree analysis of the market thoroughly delivering insights into the market for better business decisions.

Market Segmentation:

1. Global Rheumatoid Arthritis Market Research and Analysis by Treatment

The Report covers:
  • Comprehensive research methodology of the global rheumatoid arthritis market.
  • This report also includes a detailed and extensive market overview with key analyst insights.
  • An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
  • Analysis of regional regulations and other government policies impacting the global rheumatoid arthritis market.
  • Insights about market determinants which are stimulating the global market.
  • Detailed and extensive market segments with regional distribution of forecasted revenues.
  • Extensive profiles and recent developments of market players.

Table of Contents

1. Report Summary
1.1. Research Methods and Tools
1.2. Market Breakdown
1.2.1. By Segments
1.2.2. By Geography
2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendations
2.2.3. Conclusion
2.3. Rules & Regulations
3. Competitive Landscape
3.1. Company Share Analysis
3.2. Key Strategy Analysis
3.3. Key Company Analysis
3.3.1. Amgen Inc.
3.3.1.1. Overview
3.3.1.2. Financial Analysis
3.3.1.3. SWOT Analysis
3.3.1.4. Recent Developments
3.3.2. Pfizer Inc.
3.3.2.1. Overview
3.3.2.2. Financial Analysis
3.3.2.3. SWOT Analysis
3.3.2.4. Recent Developments
3.3.3. AbbVie Inc.
3.3.3.1. Overview
3.3.3.2. Financial Analysis
3.3.3.3. SWOT Analysis
3.3.3.4. Recent Developments
3.3.4. Sanofi SA
3.3.4.1. Overview
3.3.4.2. Financial Analysis
3.3.4.3. SWOT Analysis
3.3.4.4. Recent Developments
3.3.5. Bristol-Myers Squibb Co.
3.3.5.1. Overview
3.3.5.2. Financial Analysis
3.3.5.3. SWOT Analysis
3.3.5.4. Recent Developments
4. Market Determinants
4.1. Motivators
4.2. Restraints
4.3. Opportunities
5. Market Segmentation
5.1. Global Rheumatoid Arthritis Market by Treatment
5.1.1. Medications
5.1.1.1. Nonsteroidal anti-inflammatory drugs (NSAIDs)
5.1.1.2. Disease-modifying anti-rheumatic drugs (DMARDs)
5.1.1.3. Biologics
5.1.1.4. Steroidal Medications
5.1.2. Surgery
6. Regional Analysis
6.1. North America
6.1.1. United States
6.1.2. Canada
6.2. Europe
6.2.1. UK
6.2.2. Germany
6.2.3. Italy
6.2.4. Spain
6.2.5. France
6.2.6. Rest of Europe
6.3. Asia-Pacific
6.3.1. China
6.3.2. India
6.3.3. Japan
6.3.4. Rest of Asia-Pacific
6.4. Rest of the World
7. Company Profiles
7.1. AbbVie Inc.
7.2. Allergan PLC
7.3. Amgen Inc.
7.4. Anika Therapeutics, Inc.
7.5. Astellas Pharma Inc.
7.6. AstraZeneca PLC
7.7. Biogen Inc.
7.8. Boehringer Ingelheim GmbH
7.9. Bristol-Myers Squibb Co.
7.10. Celltrion Healthcare Co.,Ltd.
7.11. Eli Lilly and Co.
7.12. F. Hoffmann-La Roche Ltd.
7.13. GlaxoSmithKline PLC
7.14. Johnson & Johnson Services, Inc.
7.15. Pfizer Inc.
7.16. Regeneron Pharmaceuticals Inc.
7.17. Sanofi SA
7.18. Swedish Orphan Biovitrum AB (SOBI)
7.19. Takeda Pharmaceutical Co. Ltd.
7.20. Teva Pharmaceutical Industries Ltd.
7.21. UCB S.A.

Companies Mentioned

A selection of companies mentioned in this report includes:

  • AbbVie Inc.
  • Allergan PLC
  • Amgen Inc.
  • Anika Therapeutics, Inc.
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Biogen Inc.
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb Co.
  • Celltrion Healthcare Co.,Ltd.
  • Eli Lilly and Co.
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline PLC
  • Johnson & Johnson Services, Inc.
  • Pfizer Inc.
  • Regeneron Pharmaceuticals Inc.
  • Sanofi SA
  • Swedish Orphan Biovitrum AB (SOBI)
  • Takeda Pharmaceutical Co. Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • UCB S.A.